Cost Containment:

High-Cost Drug Solutions

Dialysis Management Solutions

Dependent Audit

Claims Audit

Gene Therapy Solutions

Gene Therapy Solutions

Developments in gene and cell therapies have the potential to provide life-changing treatments, but they also present a significant financial risk to self-funded plan sponsors and employers. When coupled with stop-loss coverage, this cost-containment program provides a sustainable strategy that prepares employers to face unexpected, high-dollar gene therapy claims with confidence.

Gene Therapy Solutions

Developments in gene and cell therapies have the potential to provide life-changing treatments, but they also present a significant financial risk to self-funded plan sponsors and employers. When coupled with stop-loss coverage, this cost-containment program provides a sustainable strategy that prepares employers to face unexpected, high-dollar gene therapy claims with confidence.

Helping employers face unexpected, high-dollar claims with confidence.

Amwins Group Benefits works with brokers to help their clients navigate the future of gene therapy by empowering them to implement smart, practical and complete risk-management programs and strategies. We bring unrivaled knowledge and expertise to our retail partners by providing meaningful solutions that protect employers as they face the ever-evolving and complex gene-therapy landscape.

Human gene therapy aims to change a gene’s expression or the biological characteristics of living cells for treating or curing disease. According to the FDA, there are 36 cellular and gene therapies in the market today and seven to 10 additional approved treatments predicted by next year. Current treatment costs range between $850,000 and $4,250,000 and are expected to continue to rise as more approved gene-therapy treatments hit the market.

Amwins Gene Therapy Solutions

The Amwins Gene Therapy Solutions program currently provides coverage for three Food and Drug Administration (FDA) approved treatments that deliver curative or life-altering solutions for hereditary blindness and spinal muscular atrophy :

Luxturna treatment for hereditary blindness up to $850,000
Zolgensma treatment for spinal muscular atrophy $2,200,000
Spinraza treatment for spinal muscular atrophy up to $2,200,000
Zynteglo treatment for hereditary blood disorder up to $2,800,000
Skysona treatment for genetic brain disease up to $3,000,000

Amwins Gene Therapy Solutions offers unique program advantages, including:

Meaningful protection

Offering first-dollar protection to the plan sponsor

Portability

Changing carriers without disrupting program terms

Seamless contract management

Eliminating an additional layer of complexity by managing contract terms

Simplified billing

Reducing administrative burden by including the program fee in the stop-loss bill

Learn More

Recent Group Benefits Headlines

Amwins Group Benefits Announces Updates to Gene Therapy Solutions Program

Amwins Group Benefits released updates to its Gene Therapy Solutions program exclusively available through Stealth Partner Group, an Amwins Company. This cost containment program, which launched in January, provides sustainable, revolutionary strategies that prepare employers to face unexpected, high-dollar gene therapy claims with confidence.

Amwins Announces New Hires Joining Stealth Partner Group and Amwins Group Benefits

Amwins, a global distributor of specialty insurance products and services, announced three new additions to the firm. Brad Mathews and Todd Marcoux will be joining the sales team at Stealth Partner Group, the largest stop-loss wholesaler in the U.S., and Kathy Phillips will be joining the ancillary practice team for Amwins’ Group Benefits division, a leading provider of employee benefits products and services.

Worcester, MA – Stealth Partner Group, an Amwins company, is excited to announce the addition of industry veteran Todd Marcoux.

During Todd’s 30 years of experience, he has worked at; a Fortune 100 company managing their insurance programs and risk management, at a reinsurance management company running a reinsurance facility and at a top 5 insurance carrier running a sales team.

Stealth Partner Group Releases 2023 State of the Market Report

Stealth Partner Group, an Amwins company and premier stop-loss general agency, released its Stop-Loss State of the Market report, providing up-to-date market intelligence on economic conditions and government policymaking, COVID-19 impact on stop-loss claims and the healthcare sector, high-cost claims conditions, emerging cellular, gene, and CAR-T therapies, carrier/MGU insights, artificial intelligence, cost-saving considerations and benchmarking data derived from Stealth's book of business.